Lisocabtagene maraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL) Meeting Abstract
| Authors: | Palomba, M. L.; Siddiqi, T.; Gordon, L. I.; Kamdar, M. K.; Lunning, M. A.; Hirayama, A. V.; Abramson, J. S.; Arnason, J.; Ghosh, N.; Mehta, A.; Andreadis, C.; Solomon, S. R.; Kostic, A.; Singh, A.; Espinola, R.; Bhatnagar, R.; Raviele, A.; Wang, M. |
| Abstract Title: | Lisocabtagene maraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL) |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401666 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.7016 |
| Notes: | Meeting Abstract: 7016 -- Source: Wos |
